Abstract:The world has witnessed of many pandemic waves of SARS-CoV-2. However, the incidence of SARS-CoV-2 infection has now declined but the novel variant and responsible cases has been observed globally. Most of the world population has received the vaccinations, but the immune response against COVID-19 is not long-lasting, which may cause new outbreaks. A highly efficient pharmaceutical molecule is desperately needed in these circumstances. In the present study, a potent natural compound that could inhibit the 3CL protease protein of SARS-CoV-2 was found with computationally intensive search. This research approach is based on physics-based principles and a machine-learning approach. Deep learning design was applied to the library of natural compounds to rank the potential candidates. This procedure screened 32,484 compounds, and the top five hits based on estimated pIC50 were selected for molecular docking and modeling. This work identified two hit compounds, CMP4 and CMP2, which exhibited strong interaction with the 3CL protease using molecular docking and simulation. These two compounds demonstrated potential interaction with the catalytic residues His41 and Cys154 of the 3CL protease. Their calculated binding free energies to MMGBSA were compared to those of the native 3CL protease inhibitor. Using steered molecular dynamics, the dissociation strength of these complexes was sequentially determined. In conclusion, CMP4 demonstrated strong comparative performance with native inhibitors and was identified as a promising hit candidate. This compound can be applied in-vitro experiment for the validation of its inhibitory activity. Additionally, these methods can be used to identify new binding sites on the enzyme and to design new compounds that target these sites.

DNA encoded peptide library for SARS-CoV-2 3CL protease covalent inhibitor discovery and profiling

Covalent DNA-Encoded Library Workflow Drives Discovery of SARS-CoV-2 Non-structural Proteins Inhibitors

Discovery of Novel SARS-CoV-2 3CL Protease Covalent Inhibitors Using Deep Learning-Based Screen

Bicyclic Peptide-Enhanced Covalent Inhibitor of SARS-CoV-2 3CL Protease

Structure-Based Design of Potent Peptidomimetic Inhibitors Covalently Targeting SARS-CoV-2 Papain-like Protease

Identification of novel and potent inhibitors of SARS-CoV-2 main protease from DNA-encoded chemical libraries

Exploring the Efficacy of Noncovalent SARS-CoV-2 Main Protease Inhibitors: A Computational Simulation Analysis Study.

Identification of unique and potent inhibitors of SARS-CoV-2 main protease from DNA-encoded chemical libraries

Discovery, synthesis and mechanism study of 2,3,5-substituted [1,2,4]-thiadiazoles as covalent inhibitors targeting 3C-Like protease of SARS-CoV-2

Discovery of SARS-CoV-2 3CLPro Peptidomimetic Inhibitors through the Catalytic Dyad Histidine-Specific Protein–Ligand Interactions

A Computer-Aided Approach for the Discovery of D-Peptides as Inhibitors of SARS-CoV-2 Main Protease

Chemical Space Profiling of SARS-CoV-2 PL pro Using DNA-Encoded Focused Libraries

Discovery and Mechanism Study of SARS-CoV-2 3C-like Protease Inhibitors with a New Reactive Group

Design and Evaluation of a Novel Peptide–Drug Conjugate Covalently Targeting SARS-CoV-2 Papain-like Protease

Potent and selective covalent inhibition of the papain-like protease from SARS-CoV-2

In-silico approaches for identification of compounds inhibiting SARS-CoV-2 3CL protease

Mechanistic investigation of SARS-CoV-2 main protease to accelerate design of covalent inhibitors

De Novo Discovery of a Noncovalent Cell-Penetrating Bicyclic Peptide Inhibitor Targeting SARS-CoV-2 Main Protease

Discovery of All-d-Peptide Inhibitors of SARS-CoV-2 3C-like Protease

Azapeptides with unique covalent warheads as SARS-CoV-2 main protease inhibitors

Identification of a Putative SARS-CoV-2 Main Protease Inhibitor Through in Silico Screening of Self-Designed Molecular Library.